Details:

Alternative Title:
Emerg Infect Dis
Publisher's site:
http://dx.doi.org/10.3201/eid1510.090310
Personal Author:
Winthrop, Kevin L.; Chang, Eric; Yamashita, Shellie; Iademarco, Michael F.; LoBue, Philip A.;
Winthrop, Kevin L.; Chang, Eric; Yamashita, Shellie; Iademarco, Michael F.; LoBue, Philip A.; Less -
Description:
Patients receiving anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapy are at increased risk for tuberculosis and other granulomatous diseases, but little is known about illness caused by nontuberculous mycobacteria (NTM) in this setting. We reviewed the US Food and Drug Administration MedWatch database for reports of NTM disease in patients receiving anti-TNF-alpha therapy. Of 239 reports collected, 105 (44%) met NTM disease criteria. Median age was 62 years; the majority of patients (66, 65%) were female, and most (73, 70%) had rheumatoid arthritis. NTM infections were associated with infliximab (n = 73), etanercept (n = 25), and adalimumab (n = 7); most patients were taking prednisone (n = 68, 65%) or methotrexate (n = 58, 55%) concurrently. Mycobacteria avium (n = 52, 50%) was most commonly implicated, and 9 patients (9%) had died at the time their infections were reported. A high rate of extrapulmonary manifestations (n = 46, 44%) was also reported.
Subject:
[+]
Humans
Immunosuppressive Agents
Mycobacterium
Mycobacterium Infections
Research
Tumor Necrosis Factor-alpha

Source:
Emerg Infect Dis. 15(10):1556-1561.;
Pubmed ID:
19861045
Pubmed Central ID:
PMC2866401
Document Type:
Journal Article;
Funding:
1K08HS017552-01/HS/AHRQ HHS/United States;
Collection(s):
Emerging Infectious Diseases
Main Document Checksum:
[+]
urn:sha256:9ef34b0c08ad84f6ba35e405743bb303101bbc9a93aee82f716964befe0b428c
File Type:

Supporting Files

• 	09-0310-F1.gif	gif
  	09-0310-F1.jpg	jpeg
  	09-0310-F2.gif	gif
  	09-0310-F2.jpg	jpeg
  	09-0310_finalR.nxml	txt
  	license.txt	txt

More +